Tumors continue to escape therapies that target single signaling pathways. A recent study in mice shows that combination immunotherapy involving different arms of immune response can overcome this and cure intractable tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Katie Vicari/Springer Nature
References
Postow, M.A., Callahan, M.K. & Wolchok, J.D. J. Clin. Oncol. 33, 1974–1982 (2015).
Topalian, S.L., Taube, J.M., Anders, R.A. & Pardoll, D.M. Nat. Rev. Cancer 16, 275–287 (2016).
Sharma, P. & Allison, J.P. Science 348, 56–61 (2015).
Moynihan, K.D. et al. Nat. Med. 22, 1402–1410 (2016).
Pulendran, B. Annu. Rev. Immunol. 33, 563–606 (2015).
Stromnes, I.M. et al. Cancer Cell 28, 638–652 (2015).
Palucka, K. & Banchereau, J. Cell 157, 516–516.e1 (2014).
Palucka, A.K. & Coussens, L.M. Cell 164, 1233–1247 (2016).
Larkin, J. et al. N. Engl. J. Med. 373, 23–34 (2015).
Hildner, K. et al. Science 322, 1097–1100 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Karolina Palucka does consulting for MedImmune and Merck, and declares grant support from Merck.
Rights and permissions
About this article
Cite this article
Palucka, K., Banchereau, J. Diversity and collaboration for effective immunotherapy. Nat Med 22, 1390–1391 (2016). https://doi.org/10.1038/nm.4249
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4249
